ResMed CEO Executes Options, Sells Nearly $1.12M in Shares After Q2 Beat
ResMed Chairman and CEO Michael J. Farrell exercised stock options to acquire 4,991 shares at $146.34 per share and sold those same shares on April 7, 2026, for a total of $1.12 million. The company posted a fiscal second-quarter EPS beat and revenue in line with expectations, prompting a range of analyst responses and price-target adjustments.